Tracers / [161Tb]Tb-RM2

[161Tb]Tb-RM2

Also written as RM2; rm2; Rm2; rM2; [Tb-161]Tb-RM2
Radionuclide
Tb-161 t½ 9907.2 min
Modality
Therapy
Production route
—
Stage
preclinical study
Syntheses indexed
2
Prostate cancerPreclinical only, no clinical indication yet

What it is

Compound class
Gastrin-releasing peptide receptor (GRPR) antagonist peptide (DOTA-conjugated, RM2)
Target / mechanism
Gastrin-releasing peptide receptor (GRPR) antagonist PMID 38124121
Clinical application
—
Theranostic pair
<a href="/tracers/ga68-rm2/">ga68-rm2</a>

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
—————RM238124121
2024 J Nucl Med
—————RM242429818
2026 Eur J Nucl Med Mol Imaging
161Tb- and 177Lu-Labeling was completed at 90 °C within 10 min (1.0 M sodium acetate buffer, pH = 5.5, molar activity of ~ 50 MBq/nmol)

Need this precursor?We can point you to suppliers for [161Tb]Tb-RM2, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68, In-111. Compound class inferred from precursor name (not stated outright) -- PMID 38124121: 'RM2 (DOTA-Pip5-d-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2)'. Stage set/updated at stage 23 from PMID 38124121: 'Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with 161Tb and 177Lu: A Comparative Study.'.